REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
05 October 2022
Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
04 October 2022
REPROCELL and Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. Find out more.
End of Q2 update from REPROCELL (2022-23)
03 October 2022
Read the end of Q2 update from REPROCELL for the financial year 2022-23. Discover the latest website updates, blog, and news updates.
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022
Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.
Life science after lockdown: SPS returns for 2022
15 August 2022
Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.
Bioserve India granted NABL accreditation in the field of Genomics Testing
09 August 2022
Bioserve Biotechnologies India Pvt Ltd has received NABL accreditation for Medical Testing in the field of Genomics Testing Services.
Completion of Clinical Phase II Trials of Stemchymal in Japan
16 May 2022
We will endeavor to obtain clinical approval as soon as possible so that we can provide the new treatment to patients suffering from this disease.
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
08 March 2022
Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.
REPROCELL spotlights the power of smarter biospecimens in new global publication
21 January 2022
REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.